Retinoblastoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019
NEW YORK, Aug. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Retinoblastoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019http://www.reportlinker.com/p0946321/Retinoblastoma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Retinoblastoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary Scope- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Retinoblastoma Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Retinoblastoma Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Retinoblastoma Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Retinoblastoma Therapeutics market
Reasons to buy- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Retinoblastoma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Retinoblastoma Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Retinoblastoma Therapeutics market landscape? – Identify, understand and capitalize.
Table of Contents1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Retinoblastoma Therapeutics - Introduction 5
2.1 Disease Overview 5
2.1.1 Most Common Pediatric Tumors 5
2.1.2 Congenital (Hereditary) and Non-Hereditary Retinoblastoma 7
2.1.3 Types of Retinoblastoma 7
2.2 Epidemiology 8
2.2.1 Incidence Rate 8
2.2.2 Survival Rate 8
2.2.3 Diagnosis Rate 8
2.2.4 Cure Rate 8
2.3 Etiology and Pathophysiology 9
2.3.1 Pathophysiology of Retinoblastoma 9
2.4 Sign and Symptoms 11
2.5 Prognosis 12
2.6 Diagnosis 12
2.6.1 Initial Diagnosis 12
2.6.2 Confirmatory Diagnosis 13
2.6.3 Grouping and Staging of Retinoblastoma 15
2.6.4 Histology 17
2.7 Treatment and Management Pattern 18
2.7.1 Management of Intraocular Retinoblastoma 20
2.7.2 Management of Extraocular Retinoblastoma 22
2.8 GlobalData Pipeline Report Guidance 23
3 Retinoblastoma Therapeutics - Market Characterization 24
3.1 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Global 24
3.2 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Global 25
3.3 Retinoblastoma Therapeutics Market Size (2006 - 2011) - The US 26
3.4 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - The US 27
3.5 Retinoblastoma Therapeutics Market Size (2006 - 2011) - The UK 28
3.6 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - The UK 29
3.7 Retinoblastoma Therapeutics Market Size (2006 - 2011) - France 30
3.8 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - France 31
3.9 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Germany 32
3.10 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Germany 33
3.11 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Italy 34
3.12 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Italy 35
3.13 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Spain 36
3.14 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Spain 37
3.15 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Japan 38
3.16 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Japan 39
3.17 Drivers and Barriers 40
3.17.1 Drivers for Retinoblastoma Therapeutics Market 40
3.17.2 Barriers for Retinoblastoma Therapeutics Market 40
3.18 Opportunity and Unmet Needs 41
3.19 Key Takeaway 41
4 Retinoblastoma Therapeutics Market - Competitive Assessment 42
4.1 Overview 42
4.2 Strategic Competitor Assessment 42
4.3 Product Profile for the Major Marketed Products in the Retinoblastoma Therapeutics Market 42
4.3.1 VEC Regimen (Vincristine + Carboplatin + Etoposide) 42
4.4 Key Takeaway 43
5 Retinoblastoma Therapeutics Market - Pipeline Assessment 44
5.1 Overview 44
5.2 Strategic Pipeline Assessment 44
5.3 Retinoblastoma Pipeline Analysis - Pipeline by Clinical Phases of Development 44
5.3.1 Retinoblastoma Therapeutics-Phase II Pipeline 44
5.3.2 Retinoblastoma Therapeutics-Phase I Pipeline 44
5.4 Retinoblastoma Therapeutics Pipeline by Mechanism of Action 45
5.5 Retinoblastoma Therapeutics Technology Trends Analytic Framework 45
5.6 Promising Drugs under Clinical Development 46
5.7 Profile for Promising Drugs 46
6 Retinoblastoma Therapeutics - Clinical Trials Mapping 47
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 47
6.2 Clinical Trials by Phase 48
6.3 Clinical Trials by Trial Status 49
6.4 Overall Sponsors 50
6.5 Prominent Sponsors 51
7 RB Therapeutics - Strategic Assessment 52
7.1 Key Events Impacting the Future Market 52
7.2 Future Market Competition Scenario 52
8 Appendix 54
8.1 Market Definitions 54
8.2 Abbreviations 54
8.3 Methodology 54
8.3.1 Coverage 55
8.3.2 Secondary Research 55
8.3.3 Forecasting 55
8.3.4 Primary Research 57
8.3.5 Expert Panel Validation 58
8.4 Contact Us 58
8.5 Disclaimer 58
8.6 Bibliography 58
List of TablesTable 1: Hereditary and Non-Hereditary Retinoblastoma 7
Table 2: Annual Incidence of Retinoblastoma in EU 5 Countries 8
Table 3: Retinoblastoma Therapeutics Market, Global, Revenue ($m), 2006 - 2011 24
Table 4: Retinoblastoma Therapeutics Market, Global, Forecast ($m), 2011 - 2019 25
Table 5: Retinoblastoma Therapeutics Market, The US, Revenue ($), 2006 - 2011 26
Table 6: Retinoblastoma Therapeutics Market, The US, Forecast ($), 2011 - 2019 27
Table 7: Retinoblastoma Therapeutics Market, The UK, Revenue ($), 2006 - 2011 28
Table 8: Retinoblastoma Therapeutics Market, The UK, Forecast ($), 2011 - 2019 29
Table 9: Retinoblastoma Therapeutics Market, France, Revenue ($), 2006 - 2011 30
Table 10: Retinoblastoma Therapeutics Market, France, Forecast ($), 2011 - 2019 31
Table 11: Retinoblastoma Therapeutics Market, Germany, Revenue ($), 2006 - 2011 32
Table 12: Retinoblastoma Therapeutics Market, Germany, Forecast ($), 2011 - 2019 33
Table 13: Retinoblastoma Therapeutics Market, Italy, Revenue ($), 2006 - 2011 34
Table 14: Retinoblastoma Therapeutics Market, Italy, Forecast ($), 2011 - 2019 35
Table 15: Retinoblastoma Therapeutics Market, Spain, Revenue ($), 2006 - 2011 36
Table 16: Retinoblastoma Therapeutics Market, Spain, Forecast ($), 2011 - 2019 37
Table 17: Retinoblastoma Therapeutics Market, Japan, Revenue ($), 2006 - 2011 38
Table 18: Retinoblastoma Therapeutics Market, Japan, Forecast ($), 2011 - 2019 39
Table 19: Retinoblastoma Therapeutics- Phase II Pipeline, 2011 44
Table 20: Retinoblastoma Therapeutics - Phase I Pipeline, 2011 44
Table 21: Retinoblastoma Therapeutics - Promising Drug Under Clinical Development, 2011 46
Table 22: Retinoblastoma Therapeutics -Clinical Trials by Region, 2011 47
Table 23: Retinoblastoma Therapeutics, Global, Clinical Trials by Phase of Development, 2011 48
Table 24: Retinoblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2011 49
Table 25: Retinoblastoma Therapeutics, Overall Sponsors, 2011 50
Table 26: Retinoblastoma Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 51
List of FiguresFigure 1: Most Common Pediatric Tumors 5
Figure 2: Solid Tumors in Pediatric Patients 6
Figure 3: Normal Retina and Retinoblastoma Tumor 6
Figure 4: Unilateral and Bilateral Retinoblastoma 7
Figure 5: The Gross Chalky White Appearance of Retinoblastoma 9
Figure 6: Molecular Genetic Mechanisms of Hereditary and Non-Hereditary Retinoblastoma 10
Figure 7: Percentage Breakdown of Common Symptoms of Retinoblastoma 11
Figure 8: Red Reflex Test to Detect Leukocoria 12
Figure 9: Major Diagnostic Tests for Retinoblastoma 13
Figure 10: CT Scan and Ultrasonography of Retinoblastoma 14
Figure 11: The Reese-Ellsworth Staging System 16
Figure 12: Histopathology Slide of Retinoblastoma 17
Figure 13: Multidisciplinary Approach in the Treatment of Retinoblastoma 18
Figure 14: Treatment Algorithm for the Management of Retinoblastoma, Unilateral 19
Figure 15: Treatment Algorithm for the Management of Retinoblastoma, Bilateral 19
Figure 16: Chemotherapy for Retinoblastoma 21
Figure 17: Orbital Implant During Enucleation 22
Figure 18: Retinoblastoma Therapeutics Market, Global, Revenue ($m), 2006 - 2011 24
Figure 19: Retinoblastoma Therapeutics Market, Global, Forecast ($m), 2011 - 2019 25
Figure 20: Retinoblastoma Therapeutics Market, The US, Revenue ($), 2006 - 2011 26
Figure 21: Retinoblastoma Therapeutics Market, The US, Forecast ($), 2011 - 2019 27
Figure 22: Retinoblastoma Therapeutics Market, The UK, Revenue ($), 2006 - 2011 28
Figure 23: Retinoblastoma Therapeutics Market, The UK, Forecast ($), 2011 - 2019 29
Figure 24: Retinoblastoma Therapeutics Market, France, Revenue ($), 2006 - 2011 30
Figure 25: Retinoblastoma Therapeutics Market, France, Forecast ($), 2011 - 2019 31
Figure 26: Retinoblastoma Therapeutics Market, Germany, Revenue ($), 2006 - 2011 32
Figure 27: Retinoblastoma Therapeutics Market, Germany, Forecast ($), 2011 - 2019 33
Figure 28: Retinoblastoma Therapeutics Market, Italy, Revenue ($), 2006 - 2011 34
Figure 29: Retinoblastoma Therapeutics Market, Italy, Forecast ($), 2011 - 2019 35
Figure 30: Retinoblastoma Therapeutics Market, Spain, Revenue ($), 2006 - 2011 36
Figure 31: Retinoblastoma Therapeutics Market, Spain, Forecast ($), 2011 - 2019 37
Figure 32: Retinoblastoma Therapeutics Market, Japan, Revenue ($), 2006 - 2011 38
Figure 33: Retinoblastoma Therapeutics Market, Japan, Forecast ($), 2011 - 2019 39
Figure 34: Opportunity and Unmet Need in the Retinoblastoma Therapeutics Market, 2011 41
Figure 35: Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma - CHP-582 43
Figure 36: Retinoblastoma Therapeutics - Pipeline by Phase of Clinical Development, 2011 44
Figure 37: Technology Trends Analytic Framework of the Retinoblastoma Therapeutics Pipeline, 2011 45
Figure 38: Technology Trends Analytic Framework of the Retinoblastoma Therapeutics Pipeline- Description, 2011 45
Figure 39: Retinoblastoma Therapeutics -Clinical Trials by Region, 2011 47
Figure 40: Retinoblastoma Therapeutics, Global, Clinical Trials by Phase of Development, 2011 48
Figure 41: Retinoblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2011 49
Figure 42: Retinoblastoma Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 50
Figure 43: Retinoblastoma Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 51
Figure 44: Retinoblastoma Therapeutics Market, Drivers and Restraints, 2011 52
Figure 45: Implications for Future Market Competition in the Retinoblastoma Therapeutics Market, 2011 53
Figure 46: GlobalData Market Forecasting Model 57
Companies Mentioned To order this report:Therapy Industry: Retinoblastoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019More
Market Research ReportCheck our
Industry Analysis and InsightsContact
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article